Case report: Enfortumab vedotin induced refractory DKA and multi organ failure – a rare fatal adverse event
There are very few therapeutic options to treat patients with locally advanced or metastatic Urothelial Cancer (UC). Enfortumab vedotin (EV) was recently approved by the FDA and has become a new therapeutic option for patients previously managed with conventional treatments. Despite its efficacy, EV...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2024-02-01
|
| Collection: | Frontiers in Oncology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1332478/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|